CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6897 result(s)

Ustekinumab (Stelara)

Last Updated: January 7, 2009
Result type: Reports
Product Line: Common Drug Review
Generic Name: Ustekinumab
Indications: Psoriasis

  • Brand Name: Stelara
  • Manufacturer: Janssen-Ortho Inc.
  • Project Number: S0156
  • Project Status: Complete
  • Submission Type: New

Anticonvulsants, Serotonin-Norepinephrine Reuptake Inhibitors, and Tricyclic Antidepressants in Management of Neuropathic Pain: A Meta-Analysis and Economic Evaluation

Last Updated: January 7, 2009
Result type: Reports

Technologies and Condition Anticonvulsants (ACs) gabapentin and pregabalin, serotonin-norepinephrine reuptake inhibitors (SNRIs) duloxetine and venlafaxine, and tricyclic antidepressants (TCAs) for the first-line treatment of neuropathic pain. Issue Given scarce resources and the introduction of new treatments, it is timely to assess the reco...

Solifenacin succinate (Vesicare)

Last Updated: January 5, 2009
Result type: Reports
Product Line: Common Drug Review
Generic Name: Solifenacin succinate
Indications: Bladder, overactive

  • Brand Name: Vesicare
  • Manufacturer: Astellas Pharma Canada Inc.
  • Project Number: S0155
  • Project Status: Complete
  • Submission Type: Resubmission